Quanergy Achieves IATF 16949 Automotive Production Certification
Quanergy Systems, Inc., a global leader in the design and development of solid state LiDAR sensors and smart sensing solutions, today announced that the production line for its solid state LiDAR sensors has achieved IATF 16949 certification.
The International Automotive Task Force (IATF) 16949 is a certification that denotes requirements for a quality management system for organizations within the automotive industry. To qualify and meet certification requirements, Quanergy’s solid state LiDAR production line underwent a thorough quantitative assessment, which consists of 113 tasks within 5 stages that are based on stringent automotive requirements and data obtained through Statistical Process Control (SPC) and Measurement System Analysis (MSA).
The qualification criteria to meet this certification requirement are critical steps towards Quanergy’s goal to bring automotive-grade solid state LiDAR sensors to market. Automotive-grade LiDAR sensors are built using rigorous production processes, which must pass tests that significantly reduce the failure rate of the sensors. While the certification process takes 24 months on average, as a result of Quanergy’s automated facilities, the company was able to gain qualification of this certification in 18 months.
“This latest certification of our production line is a monumental milestone for Quanergy and for the entire LiDAR community,” said Dr. Louay Eldada, CEO of Quanergy. “As automotive and technology companies converge towards a driverless future, the ability to produce automotive-grade solid state LiDAR sensors will be vital. As a result of our team’s hard work and commitment to achieving this certification, Quanergy is leading the way towards this reality.”
Quanergy’s vice president of quality and reliability, Bruce Shibuya, led Quanergy’s various departments and teams to meet this quality standard and achieve qualification of the IATF 16949 certification. Using advanced product quality planning (APQP), Shibuya coordinated internal teams across engineering, production, manufacturing and quality to run reliability tests on all components and completed assemblies as well as qualify the products to meet a strict set of requirements (e.g., thermal cycling, mechanical shock, electrical stress). An industry veteran, Shibuya has established high standards for product quality and reliability as the head of quality departments at companies including Toyota/Lexus, Hyundai/Kia, Nvidia and Jabil.
“IATF 16949 certification opens many doors for Quanergy, which is why our team poured so much effort into earning this distinction,” said Bruce Shibuya, Vice President of Quality and Reliability at Quanergy. “Going through this extremely rigorous process validated our understanding that Quanergy’s products are superior in terms of quality and reliability in all business segments that we are engaged in.”
This qualification of the certification follows the announcement earlier this month that Quanergy obtained another critical quality certification, ISO 9001:2015. As a result of these certifications, Quanergy will now begin mass production of its S3 solid state sensor on its newly certified line.
About Quanergy Systems, Inc.
Quanergy Systems was founded in 2012 and builds on decades of experience of its team in the areas of optics, photonics, optoelectronics, robotics, artificial intelligence, machine learning and controls. Headquartered in Sunnyvale, California, in the heart of Silicon Valley, Quanergy offers the world’s leading LiDAR sensors and software for the capture and processing of 3D spatial data, and object detection, tracking and classification. Its sensing systems improve safety, efficiency and costs in sectors ranging from transportation and security to industrial automation and 3D terrestrial and aerial mapping. In transportation, the data is utilized in real time to greatly improve the accuracy and reliability of on-board driver safety systems and enhance them with perception, scenario analysis, and decision making capability for cost-effective and robust advanced driver assistance systems (ADAS) and autonomous vehicle (AV) solutions. Quanergy’s LiDAR leads in all key commercialization areas – price, performance, reliability, size, weight, power efficiency. For more information, visit www.quanergy.com.
Quanergy Systems, Inc.
Ann Gargiulo, +1-408-245-9500
Sr. Director, Marketing Communications
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma21.10.2018 10:45 | Pressemelding
Incyte Corporation (Nasdaq:INCY) announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment. In patients with FGFR2 translocations who were followed for at least eight months, interim study results demonstrated an overall response rate (ORR) of 40 percent, the primary endpoint, and a median progression free survival (PFS) of 9.2 months, a key secondary endpoint. These results are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany in a poster presentation on Sunday, October 21 from 12:45 p.m. CEST to 1:45 p.m. CEST (6:45 a.m. ET to 7:45 a.m. ET). (Location: Hall A3 – Poster Area Networking Hub; Abstract #756P) “We are pleased to share updated interim results from our ongoing FIGHT-202 trial
Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer21.10.2018 09:10 | Pressemelding
Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy. The study met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS) consistently supported the OS results, as well as continuing to demonstrate the predictable safety and tolerability profile of trifluridine/tipiracil. Data from TAGS was presented by Dr. Hendrik-Tobias Arkenau, Executive Medical Director of the Sarah Cannon Research Institute UK and an investigator for TAGS, at the ESMO 2018 Congress in Munich, Germany during an oral session (Abstract #LBA25). The study results were simultaneously published in
Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting20.10.2018 22:30 | Pressemelding
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent
Manchester United and True Religion Launch Denim Range19.10.2018 17:37 | Pressemelding
Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion
Arch Insurance Announces Strategic Leadership Changes19.10.2018 13:10 | Pressemelding
Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 12:00 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an